Our News Bureau – Mumbai
Omkar Speciality Chemicals, manufacturers of speciality chemicals, such as selenium derivatives, iodine derivatives, molybdenum derivatives, cobalt bismuth derivatives and pharmaceutical intermediates for life saving drugs has recently forayed into the pharma business with its recent acquisition of LASA Laboratory.
Located at Mahad in Raigad district, south west of Maharashtra has been an established player in the anthelmintic/ veterinary API segment with state-of-the-art API manufacturing facility.
Pravin S Herlekar, Chairman and Managing Director, Omkar Speciality Chemicals Ltd (OSCL) said, “There is a colossal demand in the API manufacturing space, and with Indian drug
manufacturing sector gaining international prominence, the acquisition of LASA Laboratory was the right move for our group to venture into the pharma business. It is also a part of our group’s forward integration strategy.”
“The acquisition will enable us to focus on manufacturing anthelmintics, such as albendazole EP, albendazole IP/USP, cyromazine, fenbendazole BP VET/ EP, nitroxynil BP vet, ricobendazole, toldimphos sodium and triclabendazole,” informed Herlekar.
“Our new API division is already in the operation and will initially focus on continuing the existing API business of LASA Laboratory, which has massive demand in India and abroad. The
products are used as anthelmintics or deworming agents for veterinary,” Herlekar further said.
“Currently, our product portfolio comprises 10 products in the veterinary anthelmentics segment, mainly benzimidazoles and other active pharma ingredients,” he added.